GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (FRA:I4AA) » Definitions » Cyclically Adjusted FCF per Share

IntelliPharmaCeutics International (FRA:I4AA) Cyclically Adjusted FCF per Share : €-1.16 (As of Aug. 2023)


View and export this data going back to 2013. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

IntelliPharmaCeutics International's adjusted free cash flow per share for the three months ended in Aug. 2023 was €0.007. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.16 for the trailing ten years ended in Aug. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 13.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 27.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of IntelliPharmaCeutics International was 46.30% per year. The lowest was 2.90% per year. And the median was 15.10% per year.

As of today (2024-06-16), IntelliPharmaCeutics International's current stock price is €0.0445. IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share for the quarter that ended in Aug. 2023 was €-1.16. IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF of today is .


IntelliPharmaCeutics International Cyclically Adjusted FCF per Share Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted FCF per Share Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.09 -1.60 -1.26 -1.07 -

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1.31 -1.28 -1.16

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted Price-to-FCF falls into.



IntelliPharmaCeutics International Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IntelliPharmaCeutics International's adjusted Free Cash Flow per Share data for the three months ended in Aug. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=0.007/125.3885*125.3885
=0.007

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201311 -0.681 97.182 -0.879
201402 0.047 98.051 0.060
201405 0.220 99.394 0.278
201408 -0.554 99.315 -0.699
201411 -0.555 99.078 -0.702
201502 -0.060 99.078 -0.076
201505 -0.495 100.263 -0.619
201508 -0.516 100.579 -0.643
201511 -0.524 100.421 -0.654
201602 -0.677 100.421 -0.845
201605 -0.481 101.765 -0.593
201608 -1.230 101.686 -1.517
201611 0.110 101.607 0.136
201702 -0.765 102.476 -0.936
201705 -0.521 103.108 -0.634
201708 -0.458 103.108 -0.557
201711 -0.536 103.740 -0.648
201802 -0.380 104.688 -0.455
201805 -0.073 105.399 -0.087
201808 -0.259 106.031 -0.306
201811 -0.762 105.478 -0.906
201902 -0.156 106.268 -0.184
201905 -0.076 107.927 -0.088
201908 -0.045 108.085 -0.052
201911 -0.010 107.769 -0.012
202002 -0.002 108.559 -0.002
202005 0.003 107.532 0.003
202008 0.024 108.243 0.028
202011 -0.022 108.796 -0.025
202102 0.000 109.745 0.000
202105 -0.023 111.404 -0.026
202108 -0.035 112.668 -0.039
202111 -0.009 113.932 -0.010
202202 -0.015 115.986 -0.016
202205 -0.010 120.016 -0.010
202208 -0.009 120.569 -0.009
202211 -0.004 121.675 -0.004
202302 0.000 122.070 0.000
202305 0.003 124.045 0.003
202308 0.007 125.389 0.007

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


IntelliPharmaCeutics International  (FRA:I4AA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


IntelliPharmaCeutics International Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (FRA:I4AA) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (FRA:I4AA) Headlines

No Headlines